skin cancer

(AdobeStock)
September 17, 2025

Study reveals efficacy of nicotinamide for skin cancer prevention 

Overall, there was a 14% reduction in skin cancer risk. When nicotinamide was taken after a first skin cancer, the risk reduction rose to 54%.

By Tom Wilemon
(iStock image)
November 8, 2024

In-clinic reconstruction of skin cancer defects costs less than OR procedures

Researchers analyzed 1,206 patient cases and found that OR reconstruction cases had a higher median baseline cost of $2,308 compared to $987 for clinic procedures.

By Kanchana Devanathan
December 19, 2023

Melanoma, anyone?

Collegiate tennis and golf athletes aren’t using enough sunscreen according to a recent survey; meanwhile, the deadly skin cancer melanoma is on the rise.

By Paul Govern
August 8, 2023

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.

By Tom Wilemon
Research by Ann Richmond, PhD, second from left, Chi Yan, PhD, left, Kensey Bergdorf, PhD, JinMing Yang, PhD, and colleagues is leading to new insights on melanoma tumor formation and growth.
June 29, 2023

Study identifies key regulator of melanoma development

Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.

By Tom Wilemon
Luke and Susan Simons recently made a gift to establish the Susan and Luke Simons Directorship at Vanderbilt-Ingram Cancer Center.
August 11, 2022

Couple’s gift helps support immunotherapy research

Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.

By Tom Wilemon
February 24, 2022

Melanoma treatment response

Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.
By Sarah E. Glass
September 2, 2021

Using billing codes to count cancers

The billing codes in electronic health records are useful for counting skin cancers over time — an important metric for cancer risk assessment and prevention.
By Paul Govern
July 1, 2021

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.
By Tom Wilemon
March 25, 2021

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
By Tom Wilemon
December 17, 2020

Study reveals new strategy for reducing tumor growth, metastasis

A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.
By Leigh MacMillan
April 23, 2020

Study explores melanoma drug’s effectiveness

A study by Vanderbilt research-ers supports the clinical development of a new second-line treatment for metastatic melanoma.
By Tom Wilemon
August 15, 2019

Potential second-line melanoma treatment identified

A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.
By Tom Wilemon
1 2 3 4